Defining and Targeting BRAF Mutations in Solid Tumors

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• BRAF mutations occur in up to 8% of human cancers, presenting a significant therapeutic target.
• BRAF-targeted therapies (vemurafenib, dabrafenib, encorafenib) have improved outcomes in BRAF-mutated cancers, initially approved for metastatic melanoma.
• Resistance to BRAF inhibitors is a common limitation, necessitating novel treatment strategies.

Purpose of the Study:

• To review the prevalence of BRAF mutations across various human cancers.
• To evaluate the efficacy and safety of current BRAF-targeted therapies and combination strategies.
• To discuss future directions for treating BRAF-mutated solid tumors, including overcoming resistance.

Main Methods:

• Literature review of studies on BRAF mutations and targeted therapies.
• Analysis of clinical trial data for BRAF inhibitors, MEK inhibitors, and EGFR inhibitors.
• Synthesis of evidence on treatment response, safety profiles, and resistance mechanisms.

Main Results:

• BRAF inhibitors offer clinical benefit in BRAF-mutated cancers, with improved safety over older treatments.
• Combination therapy with BRAF and MEK inhibitors delays resistance and enhances efficacy.
• BRAF inhibitors combined with EGFR inhibitors show significant response in colorectal cancer.

Conclusions:

• Targeted BRAF inhibition and combination therapies are transforming cancer treatment.
• Addressing resistance and expanding use to less common mutations and tumor types are crucial for future progress.
• Continued research into BRAF-mutated cancers will refine treatment strategies and improve patient outcomes.